Results 31 to 40 of about 21,298 (206)

MiRNAs as novel adipokines : obesity-related circulating MiRNAs influence chemosensitivity in cancer patients [PDF]

, 2020
Adipose tissue is an endocrine organ, capable of regulating distant physiological processes in other tissues via the release of adipokines into the bloodstream.
Dewhurst, T, Hammond, CJ, Topham, CH, Withers, SB   +3 more
core   +2 more sources

First-line therapy in HER2 positive metastatic breast cancer. Is the mosaic fully completed or are we missing additional pieces? [PDF]

, 2016
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advanced ...
Cognetti F., Fabi A., Malaguti P., Vari S.   +3 more
core   +2 more sources

Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance

Molecular Oncology, 2016
Fulvestrant is a dose dependent selective estrogen receptor (ER) down‐regulator (SERD) used in ER‐positive metastatic breast cancer (MBC). Nearly all patients develop resistance.
Costanza Paoletti, Jose M. Larios, Maria C. Muñiz, Kimberly Aung, Emily M. Cannell, Elizabeth P. Darga, Kelley M. Kidwell, Dafydd G. Thomas, Nahomi Tokudome, Martha E. Brown, Mark C. Connelly, David A. Chianese, Anne F. Schott, N. Lynn Henry, James M. Rae, Daniel F. Hayes   +15 more
doaj   +1 more source

Multiple gene aberrations and breast cancer: lessons from super-responders. [PDF]

, 2015
BackgroundThe presence of multiple molecular aberrations in patients with breast cancer may correlate with worse outcomes.Case presentationsWe performed in-depth molecular analysis of patients with estrogen receptor-positive, HER2-negative, hormone ...
Atkins, Johnique T, Janku, Filip, Kurzrock, Razelle, Moulder, Stacy L, Stephens, Philip J, Wheler, Jennifer J, Yelensky, Roman   +6 more
core   +2 more sources

Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis

BMC Cancer, 2023
Background This network meta-analysis aimed to assess the comparative efficacy and safety of combinations involving three cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapies (ETs) in patients with metastatic or advanced breast cancer (
Yiyuan Liu, Jinyao Wu, Zeqi Ji, Lingzhi Chen, Juan Zou, Jiehua Zheng, Weixun Lin, Jiehui Cai, Yaokun Chen, Daitian Zheng, Yexi Chen, Zhiyang Li   +11 more
doaj   +1 more source

DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation [PDF]

, 2015
The acquisition of endocrine therapy resistance in estrogen receptor a (ERa) breast cancer patients represents a major clinical problem. Notch signalling has been extensively linked to breast cancer especially in patients who fail to respond to endocrine
Aifantis, Apatira, Apweiler, Brennan, Carroll, Chazotte, Chen, Coombes, Darbre, Eikesdal, Forgac, Goloubeva, Gul, Hill, Ho, Joffe, Johnston, Jones, Jones, Jones, Kane, Kang, Kocak, Lake, Le Borgne, Lendahl, Liu, Lupien, Mader, Mao, Martinez, McPherson, Medici, Meyer, Miele, Miele, Miele, Miyamoto, Nguyen, Nicolson, Roegiers, Sarkar, Schiff, Schilling, Schupbach, Sutherland, Taylor, Urbe, Vaccari, Venkanteshan, Wang, Webster, Wieczorek, Wong, Zahler   +54 more
core   +3 more sources

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Nature Communications, 2016
Fulvestrant degrades the oestrogen receptor. Here, the authors report on a clinical trial using fulvestrant and show that mutations in the oestrogen receptor alpha gene are prevalent in circulating tumour DNA and do not influence the clinical outcome of ...
Jill M. Spoerke, Steven Gendreau, Kimberly Walter, Jiaheng Qiu, Timothy R. Wilson, Heidi Savage, Junko Aimi, Mika K. Derynck, Meng Chen, Iris T. Chan, Lukas C. Amler, Garret M. Hampton, Stephen Johnston, Ian Krop, Peter Schmid, Mark R. Lackner   +15 more
doaj   +1 more source

Sulfation of afimoxifene, endoxifen, raloxifene, and fulvestrant by the human cytosolic sulfotransferases (SULTs): A systematic analysis

Journal of Pharmacological Sciences, 2015
Previous studies demonstrated that sulfate conjugation is involved in the metabolism of three commonly used breast cancer drugs, tamoxifen, raloxifene and fulvestrant.
Ying Hui, Lijun Luo, Lingtian Zhang, Katsuhisa Kurogi, Chunyang Zhou, Yoichi Sakakibara, Masahito Suiko, Ming-Cheh Liu   +7 more
doaj   +1 more source

Cyclin‑dependent kinase 4/6 inhibitors in combination with fulvestrant for previously treated metastatic hormone receptor‑positive breast cancer patients: A systematic review and meta‑analysis of randomized clinical trials

Cancer Treatment and Research Communications, 2020
Purpose: To compare the efficacy and safety profile of the combination of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and fulvestrant versus fulvestrant alone in previously treated patients with advanced hormone-receptor positive breast cancer ...
Allan Ramos-Esquivel, Gabriel Hernández-Romero, Denis Ulises Landaverde   +2 more
doaj   +1 more source

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

Breast Cancer Research, 2021
Background Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are lacking. This unmet need is mainly due
Kamila Kaminska, Nina Akrap, Johan Staaf, Carla L. Alves, Anna Ehinger, Anna Ebbesson, Ingrid Hedenfalk, Lukas Beumers, Srinivas Veerla, Katja Harbst, Sidse Ehmsen, Signe Borgquist, Åke Borg, Alejandro Pérez-Fidalgo, Henrik J. Ditzel, Ana Bosch, Gabriella Honeth   +16 more
doaj   +1 more source